Grifols, S.A. (USD) Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Grifols, S.A. (USD) Active

Avinguda de la Generalitat, 152, Barcelona, ES, 08174

Stock Price USD

Price Change

Last Dividend USD

B+

Latest Rating

GRFS's stock peer is AZN (AstraZeneca PLC)

GRFS's stock peer is BMY (Bristol-Myers Squibb Company)

GRFS's stock peer is GILD (Gilead Sciences, Inc.)

GRFS's stock peer is MRK (Merck & Co., Inc.)

GRFS's stock peer is RHHBY (Roche Holding AG)

Healthcare Drug Manufacturers - General

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

80%

Dcf Rating

60%

Return On Equity

80%

Return On Assets

20%

Debt To Equity

40%

Price To Earnings

80%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2021-06-04	2021-06-14	0.44	2.72 %	Special
2020-11-02	2020-11-09	0.20	1.18 %	Special
2019-12-03	2019-12-11	0.22	1.74 %	Semi-Annual
2019-06-10	2019-06-18	0.17	2.12 %	Special
2018-12-03	2018-12-11	0.23	2.43 %	Semi-Annual
2018-06-04	2018-06-12	0.25	2.11 %	Semi-Annual
2017-12-04	2017-12-12	0.21	1.69 %	Semi-Annual
2017-06-01	2017-06-08	0.16	1.68 %	Semi-Annual
2016-12-07	2016-12-14	0.19	2.37 %	Semi-Annual
2016-06-06	2016-06-15	0.16	2.04 %	Semi-Annual
2015-12-14	2015-12-17	0.37	2.14 %	Semi-Annual
	2015-06-15	0.34	2.12 %	Semi-Annual
	2014-12-12	0.31	0.90 %	Semi-Annual
	2014-06-13	0.29	1.28 %	Annual
	2013-06-13	0.26	0.97 %	Weekly
		0.01	0.05 %	Weekly

Recent News

Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the “Board”) expressing Mason's support for the Company's recommended slate of director candidates for election at the Ordinary General Shareholders' Meeting to be held on June 4 and 5, 2025. T.

2025-05-30 16:05:00

IBL International collaborates with Grifols on advanced biomarker panels

MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a global healthcare company and leading producer of plasma-derived medicines and innovative diagnostic solutions, to transform the specialty diagnostics market. Under this collaboration, IBL will develop biomarker panels for specialty diagnostics based on Grifols' random access, single molecule coun.

2025-04-08 09:29:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions